FINEARTS-HF Design Paper
Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial
FINEARTS-HF Gamified Intervention to Enhance Enrollment
Gamified Behavioral Science Intervention to Enhance Trial Enrollment: An Embedded Study Within the FINEARTS-HF Trial
MRA in Heart Failure: A Meta-analysis
Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis
FINEARTS-HF Spectrum of Kidney Risk
Generalizability of the Spectrum of Kidney Risk in the FINEARTS-HF Trial to U.S. Adults With Heart Failure
FINEARTS-HF Time to Benefit
Time to Significant Benefit of Finerenone in Patients With Heart Failure
FINEARTS-HF SGLT2i-Background
Effects of the Non-Steroidal MRA Finerenone with and without Concomitant SGLT2 Inhibitor Use in Heart Failure
FINEARTS-HF Age
Finerenone Improves Outcomes in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HF
FINEARTS-HF Kidney Outcomes
Finerenone and Kidney Outcomes in Patients with Heart Failure: The FINEARTS-HF Trial
FINEARTS-HF Sex
Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial
FINEARTS-HF Initial GFR Decline
Initial Decline in Glomerular Filtration Rate With Finerenone in HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF
FINEARTS-HF Outpatient
Finerenone and Outpatient Worsening Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial
FINEARTS-HF PREDICT-HFpEF Score
Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HF
FINEARTS-HF Mode of Death
Mode of Death in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial
FINEARTS-HF Glycaemic Status in HFmrEF/HFpEF
Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial
FINEARTS-HF NYHA
Finerenone and New York Heart Association Functional Class in Heart Failure: The FINEARTS-HF Trial
FINE-HEART Incident AF/AFL
Finerenone Reduces New-Onset Atrial Fibrillation Across the Spectrum of Cardio-Kidney-Metabolic Syndrome: The FINE-HEART Pooled Analysis
FINEARTS-HF Natriuretic Peptide Levels
Effects of finerenone on natriuretic peptide levels in heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial
FINEARTS-HF Improved EF
Finerenone in Heart Failure With Improved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial
FINEARTS-HF Frailty in HF
Finerenone According to Frailty in Heart Failure: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial
FINEARTS-HF Use and Dosage of Diuretics
Efficacy and Tolerability of Finerenone According to the Use and Dosage of Diuretics: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial
FINEARTS-HF Baseline Paper
Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial
FINEARTS-HF Primary Publication
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The access to the publication on NEJM has been sponsored by Bayer
FINE-HEART
Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the FINE-HEART pooled analysis of cardiovascular, kidney, and mortality outcomes
FINEARTS-HF Patients With Recent Worsening HF
Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial
FINEARTS-HF Lifetime Benefit
Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial
FINEARTS-HF Effect according to LVEF
Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure with Mildly Reduced and Preserved Ejection Fraction: a Prespecified Analysis of The FINEARTS-HF Trial
FINEARTS-HF KCCQ
Effect of finerenone on the KCCQ in patients with HFmrEF/HFpEF: A prespecified analysis of FINEARTS-HF
FINEARTS-HF Potassium
Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
FINEARTS-HF Obesity
Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: Prespecified Analysis of FINEARTS-HF
FINEARTS-HF New Onset Diabetes
Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial
FINE-HEART Type 2 Diabetes
Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials of Heart Failure and Chronic Kidney Disease
FINEARTS-HF Atrial Fibrillation in HeartFailure
Finerenone and Atrial Fibrillation in Heart Failure: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial
FINEARTS-HF KDIGO Kidney Risk
Finerenone Across the Spectrum of Kidney Risk in Heart Failure: The FINEARTS-HF Trial
FINEARTS-HF COPD in HFmrEF/HFpEF
Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial
FINEARTS-HF Win Statistics
The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS-HF
FINEARTS-HF Anemia
Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial
FINEARTS-HF Readmissions
Effects of Finerenone on Readmissions for Heart Failure: Insights from the FINEARTS-HF Trial
FINE-HEART Efficacy and Safety in HFmrEF/HFpEF
Efficacy and Safety of Finerenone in Heart Failure With Preserved Ejection Fraction: A FINE-HEART Analysis
FINEARTS-HF Blinded Drug Withdrawal
Blinded Withdrawal of Finerenone After Long-Term Treatment in the FINEARTS-HF Trial
